High-flow nasal cannula therapy for hypoxemic respiratory failure in patients with COVID-19
Introduction: High-flow nasal cannula (HFNC) therapy in patients with hypoxemic respiratory failure due to COVID-19 is poorly understood and remains controversial. Methods: We evaluated a large cohort of patients with COVID-19-related hypoxemic respiratory failure at the temporary COVID-19 hospital...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-09-01
|
Series: | Therapeutic Advances in Infectious Disease |
Online Access: | https://doi.org/10.1177/20499361211042959 |